{"name":"EA Pharma Co., Ltd.","slug":"ea-pharma-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"AJG555","genericName":"AJG555","slug":"ajg555","indication":"Irritable bowel syndrome with constipation (IBS-C)","status":"phase_3"},{"name":"AJM300","genericName":"AJM300","slug":"ajm300","indication":"Other","status":"phase_3"},{"name":"AJM347","genericName":"AJM347","slug":"ajm347","indication":"Other","status":"phase_1"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Carogra","genericName":"Carotegrast methyl","slug":"carotegrast-methyl","indication":"Ulcerative colitis","status":"marketed"}]}],"pipeline":[{"name":"AJG555","genericName":"AJG555","slug":"ajg555","phase":"phase_3","mechanism":"AJG555 is a guanylate cyclase-C (GC-C) agonist that increases intracellular cGMP to promote fluid secretion and accelerate intestinal transit.","indications":["Irritable bowel syndrome with constipation (IBS-C)","Chronic idiopathic constipation (CIC)"],"catalyst":""},{"name":"AJM300","genericName":"AJM300","slug":"ajm300","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AJM347","genericName":"AJM347","slug":"ajm347","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Carogra","genericName":"Carotegrast methyl","slug":"carotegrast-methyl","phase":"marketed","mechanism":"Integrin alpha-4/beta-1","indications":["Ulcerative colitis"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxNWjgyUGhlOS05aUFsT3dOd295Rk8zTlIteTVqcUd3anZycEpyZnVnTlUwbmZURUtya3hmR3pnai1RdUpfLVR4a1haa245OE10QURDUWlhUHVRaDFkQU4tSHoxdUlUQUhTYTJzQW9sYkpuQXZjWWI1TnBNZVloeGNKZTd5Y2pwc19VUWZnbDh1WUw3eHNRZ2hsZUJpQjB2X3VTbFNBa2FpWQ?oc=5","date":"2026-03-24","type":"pipeline","source":"BioSpace","summary":"Newron Presents 2025 Financial Results and Provides 2026 Outlook - BioSpace","headline":"Newron Presents 2025 Financial Results and Provides 2026 Outlook","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwJBVV95cUxNSXBvSjJ0ckFhWDFIZ2k2dENaVkowZGQ3enVNNHpITHNoamVKREEzSXgzSmRJSUEzOXA1S01sSmttMHlUUjNCczJ4TklrSHVoYmlwMm92QnRtT2drNHVBVEM2Z0pxbExKdFdJSnkwSV9IM1RmNm1KcU1sQkVveERDcUpsdTdiTFNGbWJub0FaQ2NiU1ZaNnNQR0ZXZzhNQUYzbjFuZFBLNG5vSko4eUd1TTNfSkxnQWkyZ1hIU2dnMDllQlZWalNMWHNvZ2RHOG9vSFhST09Wc3gwSEkyZjdROVRBcS1GTUk0VHp6U1U2Vlo5YU5qc2xNT0F2LS1HVC1pVTR3NFZsNE13eVJUUThVRGtjMXVTOWs?oc=5","date":"2026-01-07","type":"trial","source":"BioSpace","summary":"EA Pharma, a subsidiary of Eisai, Announces the Initiation of its Phase III Clinical Trial with Evenamide, a Novel Treatment for Schizophrenia, in Japan - BioSpace","headline":"EA Pharma, a subsidiary of Eisai, Announces the Initiation of its Phase III Clinical Trial with Evenamide, a Novel Treat","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxQaTNnY2NPZmxWQ1dTVHhUdU9XSUN4alNTdzhpczlyWGU4ckxtY181blVIcmJkcC05dVk2alFwTFhGRm05QVBjeHFGXzZBUWlLTXllc0N4Q2tEY2lYQjJzN1d5cVJ6YUlFMzZUcXFQV25ySkdnUTZaMFZwRmRMUkN0T2tsdmV0eFdYNXZObG05bVo4WkFoSGNqbS0xYk1IelFqSU1FRVR3?oc=5","date":"2026-01-07","type":"trial","source":"Pharmafile","summary":"EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan - Pharmafile","headline":"EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZkFVX3lxTE1kNThzU1RrU09sakFCdlJaOXVVZnZhcjg2OXpIajhaMEk4N25DaF95YXo0Tk9ZakdYRl92bnBLcXZmdkZJaG1YZzVCSFVmSFRmdHpybHhTMEdVQTJQZFNDb1dXYzExZw?oc=5","date":"2025-10-30","type":"pipeline","source":"MedPage Today","summary":"Novel Oral miR-124 Enhancer Improves Remission in Refractory UC - MedPage Today","headline":"Novel Oral miR-124 Enhancer Improves Remission in Refractory UC","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiY0FVX3lxTE91RExBQnVGSGI4OTRWUjJUR0hib1Niek9MSkxsdUJtSjl2d09XNEVPU0VaTVJxVWg3WDlVSXJuQVlKTnpocmtXNUhpLUt6QXpxNVMzY0J5SWdxa1pmVW9sejNLcw?oc=5","date":"2025-10-16","type":"pipeline","source":"Wiley Online Library","summary":"Clinical obesity and Himan-sho (obesity disease): Lessons from Japan's 25 years of experience toward a new era of obesity care - Wiley Online Library","headline":"Clinical obesity and Himan-sho (obesity disease): Lessons from Japan's 25 years of experience toward a new era of obesit","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTE9sUFVGQTlTaXJSeE54eTZsQk5rRnBONXNEeE1VQ0dkbmxEa2hjTEJLcUt1amtQdjVIR2xEOHl4YjA2SmdCbEJIU2VmazBLYlpuZUswN0Q2SnpfMTQ2S0k1cUotdllWaTBO?oc=5","date":"2025-10-09","type":"regulatory","source":"Wiley Online Library","summary":"Efficacy of luseogliflozin for renal function preservation in patients with type 2 diabetes mellitus and impaired renal function: A randomized open-label clinical trial (RESOLUTION study) - Wiley Onli","headline":"Efficacy of luseogliflozin for renal function preservation in patients with type 2 diabetes mellitus and impaired renal ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxORGtKQjgtZzh6c01UWDNqM2hjRkM2X1NLYlUxRVQ0aGw1Q1JDcDlrTEpyMUxqQ3Q5ZUxvVzRVbWZrZk90bVJieEJOUnpCaU96aFZPR19yeS1vdTVPa282dHJPU01JdHl0N05ld1JoNXBsZVVvdFZ6R0JtaEtsMlZ6NzI0bjBSMFNjVF9QbnAzajU3U3g3U003V0ZEcWtYQmltbUYtNkhLVQ?oc=5","date":"2024-07-30","type":"pipeline","source":"BioWorld News","summary":"Ensho debuts to target gut inflammation with oral α4β7 inhibitors - BioWorld News","headline":"Ensho debuts to target gut inflammation with oral α4β7 inhibitors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwJBVV95cUxPYU1ybTRWSGVHVDNFY0plOVZXQ19EbG94Y3ZsT0Y0alRCNEpNaHQxcGdpUkpFallKS2VOREJpSDNNSnZ2VVlGR0FoRURRWTVoVVlGZm11Vl82VlYxS3JHQmU2c0cyaXM4Xy1DS0RWUGI2NXZORlM3cjdKd3hza1VwRVBjU19SX3kzZlMxMFVmcW1LcmMzcGZEU1FDUTNMNzQ3cloyWFJNTl9vWXMxemtiNVJwRXRHc3RMU0ZnTUd3UFgyTFgzUTBMOHpBSnJQejFWZW9PMkRvWUwwcXljWWxPREFWbVpKT2V6RGVTUEFibzRrWUdSbFRVY0ItNjMweGl3LXpLMHVQRV9PU1E?oc=5","date":"2024-06-27","type":"trial","source":"GlobeNewswire","summary":"Ensho Therapeutics Launches with Phase 2-Ready Oral α4β7 Inhibitor for Inflammatory Bowel Disease - GlobeNewswire","headline":"Ensho Therapeutics Launches with Phase 2-Ready Oral α4β7 Inhibitor for Inflammatory Bowel Disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxOMlFSN2RwVGhWcVNKaW1wZjhZR2Y4NTg2NkVSeERmWGMtUDNKMlZnZ1NpZC1TSTNubFo2TFJCZXpOQV9QOXNVNDN5ai1VWGtXMjUtSVoyNU9hVHp3cjRiZ0MyczFkeUdSWEpncFBvRDl5dGVsdE1nOWJHTzNaeXN6c1JFZzBjTTM0NlpRclhNbEJvUHliWnltVmR2MHprX1QwTGtnUXRFeVFvb2E1?oc=5","date":"2022-06-25","type":"pipeline","source":"BioPharma APAC","summary":"Eisai Launchs Bile Acid Transporter Inhibitor Goofice in Thailand - BioPharma APAC","headline":"Eisai Launchs Bile Acid Transporter Inhibitor Goofice in Thailand","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxQX3FnU1ZSYVRsYWU2Sk9sLUY2SFo5cTBmY3V5dElKLVZQdXJySmRpckp3VFZhMTV0Xzg3RlZzcVNEQXlCTENSUEJUZ3pOcUlpdkhjaF9VcjlzZjFLeGJZWnRmWE40VkNON2tTZW5MN2tqQ2FwU1R0UnVUa0hJWTYyaVJZYzM5OVFOR0pVbmZLelAtOEF6SUZsaHQ2MEtwUWlyYWJsNzhYYXhGTE81ZVBmOXdVWGloMW50Z3NncU5VLVp1d25aYzBZRlVzTElrQVBHcEZVWl9YdTdxLWEwWTlaYXJMN3N6Q3ZPcnc?oc=5","date":"2022-03-01","type":"pipeline","source":"prnewswire.com","summary":"Pathalys Pharma, Inc. Launches with Mission to Address High Priority Needs in Chronic Kidney Disease - prnewswire.com","headline":"Pathalys Pharma, Inc. Launches with Mission to Address High Priority Needs in Chronic Kidney Disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTE9NTjRPcGoxcTZGSnFXVm9fN3dnU19vTUxWdkdzRVYwdjdhcVk2SnJZcExpTk1iV1U5S3JFSUtneGFadHlCNnJGUWdlTjN3ZmpYMGxBcjB6MjAxbzNX?oc=5","date":"2018-11-29","type":"pipeline","source":"Eisai","summary":"MOVICOL® Launched in Japan - Eisai","headline":"MOVICOL® Launched in Japan","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxPSzdOZGZYM0lnRXR1RkdYeC1oT3o2eUpwNHNqUWFwTjYwczZ6RU9KSDRZdWlXV3NYQVpGeTl1NHNSMDNrMDZDUTZVZGgxRWNtNFdVVFdxVkpaOTI4WjZEWF92ZnFXcWQxVzNOLWVKQWNuTG9CeDBBWlRxOE1KR1RfcTdXM19sX28?oc=5","date":"2015-10-15","type":"pipeline","source":"味の素株式会社","summary":"THE GASTROINTESTINAL DISEASE BUSINESS OF EISAI CO., LTD. AND - 味の素株式会社","headline":"THE GASTROINTESTINAL DISEASE BUSINESS OF EISAI CO., LTD. AND - 味の素株式会社","sentiment":"neutral"}],"patents":[],"drugCount":4,"phaseCounts":{"phase_3":2,"phase_1":1,"marketed":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}